US-based contract research organisation QPS Holdings (QPS) has implemented a new clinical trial pharmacovigilance system, Oracle Argus, to advance safety case management in clinical trials.
The adoption aims to improve regulatory compliance, patient safety, and operational standards across drug development activities for QPS clients globally.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The integration of Oracle Argus enables QPS to better capture, manage, and report adverse events in line with global regulatory requirements.
Key benefits include improved support for client safety monitoring, increased traceability throughout clinical development stages, optimised pharmacovigilance workflows, and greater efficiency in global regulatory submissions.
As demand for new therapies rises worldwide, contract research organisations such as QPS are emphasising their role in balancing rapid development timelines with patient safety.
By leveraging the Oracle Argus platform as its clinical trial pharmacovigilance system, QPS aims to meet the requirements of pharmaceutical sponsors seeking advanced research services.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataQPS operates as a global contract research organisation with over 1,200 employees across Asia, Europe, India, and the US.
The company offers bioanalysis, discovery, preclinical and clinical development services and holds experience in areas including drug metabolism and pharmacokinetics (DMPK), pharmacology, translational medicine, toxicology, central safety labs, peripheral blood mononuclear cell (PBMC) processing, multi-site research operations, and Phase I/II clinical units.
QPS executive vice-president Derek Grimes said: “Ensuring patient safety and data integrity is at the heart of what we do when conducting clinical trials.
“Oracle Argus provides us with a robust, scalable solution to support the growing needs of our customers’ clinical trial portfolios and the evolving expectations of regulatory authorities worldwide.”
Oracle Health and Life Sciences executive vice-president and general manager Seema Verma said: “Oracle Argus provides QPS Holdings with a trusted, globally recognised drug safety platform that supports compliance with stringent pharmacovigilance standards and regulations while streamlining end-to-end safety operations and insights at scale.
“With our industry-leading solutions, QPS Holdings can further transform and elevate its safety case management for customers worldwide.”
In January 2025, Ryght AI announced a strategic collaboration with QPS Holdings to optimise clinical trial processes on a global scale.
